Skip to main content

Table 2 Characteristics of previously published studies for CI vs. IB of beta-lactam antibiotics

From: Continuous beta-lactam infusion in critically ill patients: the clinical evidence

Study Setting (country) Test antibiotic Critically ill? Patient population Sample size Age (yr) a Allocation sequence generator Allocation concealment Masking Concomitant antibiotics
CI IT
Angus et al. [87] Not specified (Thailand) Ceftazidime Yes Septicemic melioidosis 21 48 (29–58) 43 (27–73) Not specified Not specified Not specified Amx/clv or doxy, tmp/smx and chlora
Bodey et al. [89] Non-ICU (USA) Cefamandole No Malignant diseases with neutropenia 204 Not specified Adequate Adequate Not specified Carbenicillin
Buck et al. [81] Non-ICU (Germany) Pip/tazo No Hospitalized infections 24 60-88b 32-76b Not specified Adequate No Nil stated
Buijk et al. [52] ICU (Netherlands) Ceftazidime Yes Intra-abdominal infections 18 12 (46–76) 6 (42–87) Not specified Not specified No Various
Georges et al. [80] ICU (France) Cefepime Yes Critically ill with gram-negative infections 50 50 ± 17 46 ± 24 Not specified Not specified No Amikacin
Hanes et al. [86] ICU (USA) Ceftazidime Yes Critically ill trauma 32 33.5 ± 12.5 36.1 ± 12.8 Not specified Not specified No Nil stated
Kojika et al. [82] Not specified (Japan) Meropenem No Intra-abdominal infections 10 67.4 ± 14.6 60 ± 12.8 Not specified Not specified No Nil stated
Lagast et al. [88] Not specified (Belgium) Cefoperazone No Gram-negative septicaemia 45 37-77b Not specified Not specified No Nil stated
Lau et al. [79] ICU (USA) Pip/tazo No Complicated intra-abdominal infections 262 50.4 ± 16.6 49.3 ± 17.8 Not specified Not specified No Nil stated
Lubasch et al. [83] Not specified (Germany) Ceftazidime No Hospitalized patients with COPD exacerbation 81 65.3 ± 10.1 Not specified Not specified No Nil stated
Nicolau et al. [84] ICU (USA) Ceftazidime Yes Critically ill patients with sepsis 41 46 ± 16 56 ± 20 Adequate Not specified No Tobramycin
Pedeboscq et al. [85] ICU (France) Pip/tazo Yes Severe sepsis 7 58 ± 12 Not specified Not specified No Ofloxacin
Rafati et al. [78] ICU (Iran) Piperacillin Yes Critically ill patients with sepsis 40 50.1 ± 22.2 48.0 ± 20.7 Not specified Not specified No Amikacin
Roberts et al. [75] ICU (Australia) Ceftriaxone Yes Critically ill patients with sepsis 57 43 ± 19 52 ± 16 Adequate Adequate Adequatec Multiple depending on indication
Sakka et al. [77] ICU (Germany) Imi/cila Yes Critically ill patients with sepsis 20 62 ± 16 59 ± 16 Not specified Adequate No Nil stated
Van Zanten et al. [76] Not specified (Netherlands) Cefotaxime No Hospitalized patients with COPD exacerbation 93 65.3 ± 8.4 68.6 ± 5.3 Not specified Not specified No Nil stated
  1. CI, continuous infusion; IB, intermittent bolus; Amx/clv, amoxicillin/clavulanic acid; doxy, doxycycline; tmp/smx, trimethoprim/sulphamethoxazole; chlora, chloramphenicol; pip/tazo, piperacillin/tazobactam; Imi/cila, imipenem/cilastatin; COPD, chronic obstructive pulmonary disease.
  2. aValues are described as published results as mean (±SD) or median (range).
  3. bValues are reported as range.
  4. cOnly outcome assessment.